BioXcel Therapeutics Inc (NASDAQ:BTAI)’s share price gapped up prior to trading on Friday . The stock had previously closed at $8.97, but opened at $23.85. BioXcel Therapeutics shares last traded at $36.97, with a volume of 4,663,335 shares changing hands.
Several equities research analysts have issued reports on BTAI shares. Canaccord Genuity raised their price objective on shares of BioXcel Therapeutics from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, December 31st. BMO Capital Markets reaffirmed a “positive” rating and issued a $26.00 target price on shares of BioXcel Therapeutics in a research report on Thursday, January 16th. ValuEngine downgraded BioXcel Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, December 16th. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of BioXcel Therapeutics in a report on Wednesday, February 5th. Finally, SunTrust Banks started coverage on BioXcel Therapeutics in a report on Tuesday, November 12th. They set a “buy” rating and a $24.00 price target for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. BioXcel Therapeutics presently has an average rating of “Buy” and an average price target of $23.80.
The company has a debt-to-equity ratio of 0.03, a current ratio of 5.04 and a quick ratio of 5.04. The stock’s 50-day moving average price is $16.34 and its 200-day moving average price is $9.74. The company has a market cap of $381.98 million, a P/E ratio of -18.12 and a beta of 3.73.
Hedge funds and other institutional investors have recently bought and sold shares of the business. UBS Group AG boosted its holdings in BioXcel Therapeutics by 16.5% in the 4th quarter. UBS Group AG now owns 93,084 shares of the company’s stock valued at $1,360,000 after purchasing an additional 13,182 shares during the period. Banco Bilbao Vizcaya Argentaria S.A. bought a new position in shares of BioXcel Therapeutics during the fourth quarter worth approximately $730,000. Oxford Asset Management LLP bought a new position in shares of BioXcel Therapeutics during the fourth quarter worth approximately $281,000. Game Plan Financial Advisors LLC bought a new position in shares of BioXcel Therapeutics during the fourth quarter worth approximately $183,000. Finally, Barclays PLC raised its position in shares of BioXcel Therapeutics by 133.5% in the fourth quarter. Barclays PLC now owns 6,940 shares of the company’s stock valued at $101,000 after buying an additional 3,968 shares in the last quarter. 22.54% of the stock is owned by hedge funds and other institutional investors.
About BioXcel Therapeutics (NASDAQ:BTAI)
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.
Further Reading: What is a capital gain?
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.